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Abstract
To attain effective and safe pharmacotherapy, formulations in (pre)term neonates should enable extensive dose flexibility. 
During product development and subsequent authorization and clinical use of such formulations, there is also a need for 
informed decisions on excipient exposure: in addition to the need to improve the knowledge on active compounds, there 
is a similar need to improve the knowledge on excipients in neonates. Excipients are added to formulations as co-solvent, 
surfactant, preservative, colorant and/or sweetener as vehicle(s) to result in a suitable (e.g. taste, shelf life, stability) product. 
Progress has been made in the awareness, knowledge and access to this knowledge on the clinical pharmacology of excipients 
in neonates. This is thanks to different initiatives focussing on epidemiological data, excipient pharmacokinetics, or build-
ing datasets to create this knowledge. We highlight the Safe Excipient Exposure in Neonates and Small Children (SEEN) 
and propylene glycol project to illustrate the feasibility to build knowledge, and discuss the methods applied and problems 
observed during these studies. The information generated in these and other studies (European Study on Neonatal Exposure 
to Excipients, ESNEE) should be integrated in repositories like the Safety and Toxicity of Excipients for Paediatrics (STEP) 
to facilitate access to all stakeholders. This merged knowledge should have impact and assist in improving the quality of 
risk assessment and decision making during drug development, applying a risk-benefit framework (explicit justification of 
excipients, plan product development early and engage all stakeholders, data sharing and modeling, challenges related to 
new excipients, context sensitive risk-benefit analysis).
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Key Points 
In addition to the need to improve the knowledge on the 
clinical pharmacology of active compounds, a similar 
effort is needed for excipients in neonates.
Case series on relevant toxicity due to excipient exposure 
(such as propylene glycol, benzyl alcohol) are primarily 
described in preterm neonates, but also occur in term 
neonates and infants.
Studies on the pharmacokinetics and safety or toxicity 
of excipients have been performed, and this informa-
tion should be summarized and integrated in the STEP 
(Safety and Toxicity of Excipients in Pediatrics) reposi-
tory.
The merged knowledge from the STEP database and 
other sources should help to improve the quality of risk 
assessment and decision on excipient use, applying a 
risk-benefit framework.
Guidelines on excipients by authorities such as European 
Medicines Agency (EMA) or US Food and Drug Admin-
istration (FDA) are available but evolve because of the 
ongoing research and increasing knowledge. A thresh-
old concept has been introduced recently; however, the 
threshold is a value, equal to or above which it is neces-
sary to provide the information in the leaflet and is not a 
safety limit. This reflects the still limited performance to 
convert knowledge into guidelines and practice.
1 Introduction
When physicians prescribe a given drug to a neonate, this is 
with the intention of providing effective relief for a specific 
indication (e.g. pain, seizures, infection, or blood pressure), 
while also avoiding disproportional side effects. In addition 
to the active substance(s), drug formulations usually con-
tain excipients, like additives or solvents. Excipients can be 
defined as any substance formulated alongside the active 
ingredient in a specific drug formulation. Such excipients 
are added to, for example, ensure stability or solubility of 
the formulation over a documented shelf life during various 
external conditions, or to improve palatability. Moreover, 
surfactants can be added to mix or dissolve active substances 
or to facilitate administration or absorption of active sub-
stances. Excipients can also be used as bulk products in for-
mulations that otherwise contain a too highly concentrated 
active ingredient to facilitate more accurate and conveni-
ent dosage. Some examples of excipients for these differ-
ent functions are ethanol, propylene glycol, benzyl alcohol, 
parabens, lactose, mannitol, aspartame, or poly-ethylene 
glycol [1–5].
In essence, almost all drug formulations contain excipi-
ents that have been used for many years and are considered 
to have a Generally Regarded As Safe (GRAS) status. How-
ever, excipient exposure can be relevant for specific individ-
ual patients like lactose exposure in lactose-intolerant cases 
or interfering with a ketogenic diet, or aspartame exposure 
in phenylketonuria cases. The same holds true for specific 
(sub)populations such as (pre)term neonates in whom expo-
sure to, for example, ethanol or propylene glycol, may result 
in maturational toxicity, because of population-specific dif-
ferences in pharmacokinetics (PK) or pharmacodynamics 
(PD) [1–5]. Neonates and primarily pre-term neonates may 
not be able to clear an excipient in the same way (rate, and 
route) as adults, because of their physiological and devel-
opmental immaturity. This (sub)population aspect is also 
considered by authorities like the Committee for Medici-
nal Products for Human Use, that states “excipients to be 
used in formulations for the pediatric population should be 
selected with special care, and possible sensitivities of the 
different age groups should be taken into consideration” [6]. 
While there is also a new guideline to provide quantitative 
information on the excipients in the Summary of Product 
Characteristics (SmPC, the leaflet) for new formulations, 
age-appropriate (and excipient-low) drug formulations are 
still lacking [1–5]. As a result, neonates may be at risk of 
relevant excipient exposure causing clinical harm [7].
We first report on some historical and contemporary 
observations to illustrate the relevance of this topic. This is 
followed by an overview on the available epidemiological 
observations on excipient exposure in neonates, and recent 
data on the increasing knowledge on the PK of specific 
excipients in neonates. The Safe Excipient Exposure in Neo-
nates and Small Children (SEEN) project and the propylene 
glycol project are used to illustrate the feasibility to make 
progress, and to discuss the methods applied and problems 
observed during these studies. This is followed by some sug-
gestions on how to turn the knowledge generated to improve 
the quality of risk assessment and decision making during 
the drug development process.
2  Excipient‑Related Problems in Neonates: 
Historical and Contemporary 
Observations
To illustrate the relevance of excipients in neonates, we dis-
cuss historical observations on propylene glycol, polysorb-
ate, and benzyl alcohol toxicity. While all these observations 
were reported in the 1980s, similar observations on ethanol 
and propylene glycol (side)effects have been reported more 
recently, illustrating the difficulties to translate knowledge 
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into guidance and practice [1, 8]. Propylene glycol toxic-
ity in preterm neonates (< 1500 g) has been observed after 
prolonged (at least 5 days) exposure of up to 3000 mg/day 
[9, 10]. Such a significant exposure was due to high con-
centrations as solvent in parenteral nutrition formulations. 
The toxicity was in part biochemical in nature as reflected 
by hyperosmolarity, lactic acidosis, creatinine, or bilirubin, 
but exposed neonates also displayed clinically relevant side 
effects such as seizures or intracranial hemorrhage. The 
same group estimated that the elimination half-life of pro-
pylene glycol was 10–31 h in neonates, compared to 2–5 h 
in adults. At that time, the authors were not able to fur-
ther explore the interindividual PK variability [9, 10]. A 
polysorbate-related toxidrome (thrombocytopenia, renal 
dysfunction, hepatomegaly and ascites) was observed after 
a new vitamin E supplement (containing 9% polysorbate 80 
and 1% polysorbate 20) was introduced to neonates [11]. 
As summarized by Balistreri et al, it resulted in the death 
of 38 neonates, and 43 other cases sustained serious effects 
with an overrepresentation of low birth-weight infants [12]. 
Similar, benzyl alcohol-related (bacteriostatic excipient) 
mortality has been described in preterm neonates [13, 14]. 
Following at least a minimal exposure of 130 mg/kg/day, 
these preterm neonates displayed a raised Anion Gap and 
metabolic acidosis from the second day of exposure to ben-
zyl alcohol. This was followed by progressive bradycardia, 
gasping, clinical seizures and subsequent death. Following 
this observation, mechanistic evidence has been generated 
that this clinical picture relates to maturational deficiency 
of benzyl alcohol degradation to benzoic acid with subse-
quent metabolic clearance to hippuric acid. The accumula-
tion of benzoic acid in plasma subsequently explains the 
raised Anion Gap [13, 14]. As a result, benzyl alcohol is now 
contraindicated for use in neonates and of special concern 
in young children aged < 3 years [15]. Still, the potential 
side effects of this and other excipients need consideration 
in contemporary neonatal pharmaceutical care and are not 
just historical events.
In March 2011, the US Food and Drugs Administration 
(FDA) notified healthcare professionals of serious health 
issues in premature neonates exposed to a lopinavir/ritonavir 
oral (Kaletra) solution, an antiviral combination drug for the 
treatment of HIV infection [16]. This oral lopinavir/ritona-
vir solution contains relevant amounts of propylene glycol 
(152.7 mg/mL) and ethanol (356.3 mg/mL), The claimed 
mechanism for the serious health issues in neonates—based 
on the reported side effects (cardiac, renal, respiratory)—
was that neonates have a decreased propylene glycol clear-
ance and that this resulted in accumulation. The notification 
also resulted in a revision of the label (“the use of Kaletra 
oral solution should be avoided in premature babies until 
14 days after their due date, or in full-term babies younger 
than 14 days of postnatal age unless a healthcare professional 
believes that the benefit of using Kaletra oral solution to 
treat HIV infection immediately after birth outweighs the 
potential risks. In such cases, FDA strongly recommends 
monitoring for increases in serum osmolality, serum cre-
atinine, and other signs of toxicity”) [16]. More recently, it 
has been documented that the toxidrome is likely due to an 
excipient-excipient interaction. Ethanol and propylene glycol 
in neonates are almost exclusively eliminated by metabolic 
clearance through alcohol dehydrogenase (ADH) [17]. Even 
more recently and following the publication of a randomized 
controlled trial on neonatal abstinence syndrome (shorter 
duration of treatment and shorter length of hospital stay for 
sublingual buprenorphine vs oral morphine), Christiansen 
raised the question to what extent the amount of ethanol in 
the buprenorphine formulation (0.075 mg/mL, containing 
30% ethanol, 0.016 mg/kg/day) could in part explain the 
differences in neonatal abstinence syndrome (NAS) symp-
toms [18, 19]. In fact, this formulation does result in ethanol 
exposure above the ethanol threshold defined by EMA [20].
3  On the Epidemiology of Excipient 
Exposure in Neonates
As mentioned earlier, almost all drug formulations contain 
excipients. To enable researchers to focus on the relevant 
excipients, a list excipients of interest (EOI) has been sug-
gested [21]. It seems that this list has been driven by the 
clinical reports on adverse events associated with specific 
excipients as reported in the literature or to the authorities 
[21]. This list has subsequently been used as tool for research 
prioritization, like the ESNEE (European Study on Neona-
tal Exposure to Excipients) study [22]. These EOI (n = 8) 
are parabens, benzoates, benzalkonium chloride, saccharin 
sodium, sorbitol, propylene glycol, ethanol and polysorbate 
[5, 21, 22]. In two recent systematic reviews on the epidemi-
ology of EOI exposure, the incidence of neonates exposed to 
EOI was 39–100% [1, 5]. Similarly, 27–68% of the products 
administered to neonates contained EOI [1, 5].
This focused approach also enabled researchers to map 
EOI exposure in different regions or countries, hereby illus-
trating the heterogeneous pattern and variability in prod-
uct availability with or without EOI exposure throughout 
Europe. It turned out that EOI-free formulations were avail-
able for a substantial number of formulations currently 
administered to European neonates. Replacement of the 
most frequently used formulations may spare almost half 
of the neonates from unnecessary EOI exposure [23]. As a 
theoretical experiment and using the availability of the same 
active pharmaceutical ingredient with a similar dosage form 
(but not similar strength/concentration) as prerequisite for 
a ‘useful/appropriate’ substitution, this potentially resulted 
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in relevant reduction of prescriptions with EOI exposure 
(30.5–15%) and an important decrease in EOI exposed neo-
nates (63–35%) [23].
Unfortunately, substitution comes with its own issues. 
These include regulatory (legal framework of national 
authorities, responsibilities of individual physicians or 
pharmacists, the validity of national product registrations, 
international transport), financial (shipment costs, lack of 
reimbursement), and logistics related (differences in con-
centrations, storage) issues [23, 24]. To further illustrate 
this, product substitution may enforce a change in product 
concentration and subsequent change in volume adminis-
tered, and neonates may not tolerate such substitution. A 
formulation may be the result of an extemporaneous pro-
duction, but excipient content in these products is not easily 
retrievable and quality of such products varies. Moreover, 
excipient quantities are considered a protected trade infor-
mation, and this complicates acquirement of information on 
excipient levels in generic medicinal products [25]. To avoid 
such obstacles, full disclosure of excipient content in SmPCs 
for licensed products and availability of product monographs 
for extemporaneous products should be endorsed by relevant 
medicines agencies like the EMA [26]. In our opinion, this 
should not be limited to formulations that result in excipient 
exposure beyond the tolerance limits.
3.1  The SEEN (Safe Excipient Exposure in Neonates 
and Small Children) Project
To evaluate the safety issues and potential health problems 
related to excipient exposure, quantitative exposure esti-
mates are needed. With the SEEN project, a Danish group 
of researchers aimed to describe patterns of excipient expo-
sure, including a quantification of the daily cumulative dose 
of selected (and potentially harmful) excipients in neonates 
and small children during multidrug exposure. The SEEN 
project was approved by The Danish Data Committee (ID: 
BFH-2015-072, suite number: 04167) and was registered at 
ClinicalTrials.gov (identifier: NCT02545712). The Board 
for Patient Safety, Danish Health and Medicines Author-
ity (ID: 3-3013-1343/1) waived the need for patient con-
sent. The SEEN-project was a retrospective study including 
hospitalised patients aged ≤ 5 years admitted to either the 
neonatal, pediatric or other departments at the “National 
Hospital” in Copenhagen, Denmark within a 2-year period. 
The purpose was to quantify the daily cumulated dose of 
selected EOI [ethanol, propylene glycol, benzyl alcohol, par-
abens (methyl-hydroxybenzoate, sodium associate methyl-
hydroxybenzoate, propyl-hydroxybenzoate), or artificial 
sweeteners (acesulfame potassium, aspartame, glycerol, 
sorbitol, polysorbate-80)] administered to these patients [3, 
25]. The SEEN-project further relied on theoretical calcula-
tions to estimate the extent of excipient exposure in neonates 
and infants. Calculations hereby assumed 100% absorption 
of excipients, ignoring the influence of routes of administra-
tion and absorption ontogeny. Since proven safety limits of 
exposure to ethanol and propylene glycol are not available, 
threshold levels were used to assess ‘inadvertent exposure’. 
For benzyl alcohol, any exposure is contraindicated in chil-
dren aged < 3 years.
All data were manually extracted from electronic patient 
systems (medicinal and patient charts) and the study only 
included medicinal products with verified administra-
tion. All included medicinal products were explored with 
regard to excipient content in both quality and quantity. For 
licensed and unlicensed products, the SmPCs were scruti-
nized to identify potential excipients. For medicinal products 
where either the SmPC was not retrieved or the excipient 
amount was not disclosed in SmPC, manufacturers were 
contacted. For extemporaneous products, excipient content 
was retrieved from restricted databases or following direct 
contact to responsible pharmacies. Excipient exposure was 
calculated as daily cumulative levels (in mg excipient/kg 
body weight/day) based on all excipient containing admin-
istrations [25]. Daily cumulative excipient levels were com-
pared with threshold values suggested in a guideline on 
excipients published by the EMA [26]. The threshold hereby 
is a value equal to or above which it is necessary to provide 
the information, it is not a safety limit. Patients were strati-
fied according to age, and exposure to excipients. For further 
information on study design, we refer to the published study 
protocol [3]. In this review, we highlight already published 
data to describe patterns of exposure to ethanol, propylene 
glycol and benzyl alcohol [25].
Based on 1204 screened charts, 630 patients (470 neo-
nates and 160 infants aged ≤ 2 years) were included, receiv-
ing 4207 prescriptions for 316 medicinal products. Neonates 
were administered a median of 5 (SD ± 3) unique medici-
nal products and infants were administered a median of 9 
(SD ± 5) unique medicinal products. Ethanol, propylene 
glycol and benzyl alcohol were used as excipient in 8.8% 
(n = 28), 6.0% (n = 19), and 2.8% (n = 9) of administered 
medicinal products, respectively. Following contact with 
manufacturers, excipient quantities remain missing in five 
products containing ethanol (18%), eight containing propyl-
ene glycol (42%) and one containing benzyl alcohol (11%). 
In total, 45% (n = 288) of patients were exposed to either 
ethanol, propylene glycol or benzyl alcohol. Of all included 
patients, 38%, 23% and 2% were exposed to ethanol, propyl-
ene glycol and benzyl alcohol, respectively.
Among patients exposed to ethanol, proposed tolerance 
limits were exceeded in 53 and 62% of the exposed neo-
nates and infants, respectively. Among patients exposed to 
propylene glycol, proposed tolerance limits were exceeded 
in 40% of exposed neonates and 57% of exposed infants. 
Further, proposed tolerance limits of benzyl alcohol were 
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exceeded for all exposed neonates and infants. Concomitant 
exposure to ethanol, propylene glycol and benzyl alcohol 
was common: 59 neonates (12.6%) and 39 infants (24.4%) 
were exposed to both ethanol and propylene glycol, while 11 
of 14 patients exposed to benzyl alcohol were concomitantly 
exposed to ethanol and/or propylene glycol. Further, 51% of 
all 334 prescriptions of ethanol-containing medicinal prod-
ucts would result in ethanol exposure levels above proposed 
tolerance limit. For propylene glycol, 100% of 149 prescrip-
tions of medicinal products with known excipient content 
would alone exceed proposed neonatal tolerance limit and 
70% of prescriptions would alone exceed tolerance limit for 
infants.
The SEEN project hereby mirrors previous studies, since 
all these studies documented frequent excipient exposure in 
neonates and infants [27–30]. However, it adds information 
on how daily cumulative levels of ethanol, propylene glycol 
and benzyl alcohol often exceed excipient-specific tolerance 
limits proposed by the EMA. As demonstrated for Kaletra, 
these excipients may interact [16, 26, 31–33]. The SEEN 
project documented that concomitant exposure to ethanol 
and propylene glycol is common, which thus emphasizes 
the need for continuous focus on excipient exposure in this 
population and on access to the relevant data and informa-
tion [34].
4  Studies on Pharmacokinetics 
and Dynamics of Excipients in Neonates
The earlier-mentioned EOI list (parabens, benzoates, ben-
zalkonium chloride, saccharin sodium, sorbitol, propylene 
glycol, ethanol and polysorbate 80) has also been used to 
conduct focused studies on the PK and PD of excipients in 
neonates [21, 22]. This includes assay development and sub-
sequent collection of concentration-time profiles, as can be 
illustrated for methyl and propyl parabens or propylene gly-
col [35, 36]. For methyl parabens, oral bio-availability and 
subsequent clearance were driven by postnatal age (21 days 
dichotomous, 0.57 vs 0.88 L/h) [37]. Similarly, the available 
information on ethanol PK in neonates has recently been 
summarized [32]. The feasibility and problems related to 
such studies are subsequently illustrated using the experi-
ence built during the propylene glycol research project.
4.1  The Propylene Glycol Research Project
Propylene glycol accumulation potentially results in hyper-
osmolarity, lactic acidosis or hepato-renal toxicity [9, 10]. 
Consequently, observations on PK and PD in neonates were 
needed. Following approval by the Ethics Committee of the 
University Hospitals Leuven (B-32220084836), sources of 
propylene glycol exposure in neonates were retrieved as a 
first step, and we subsequently decided to collect obser-
vations in neonates exposed to intravenous (IV) diphan-
toine (8 mg/mg), paracetamol (0.8 mg/mg), phenobarbital 
(3.5 mg/mg) or digoxin (1656 mg/mg). This approach ena-
bled us to study propylene glycol disposition in neonates 
exposed during clinical care and using a scavenged sampling 
approach. An assay for blood and urine was subsequently 
developed and validated [36]. Non-linear mixed-effect 
modeling tools were subsequently used to enable analysis 
of sparse and unbalanced datasets. Additionally, this enabled 
exploration of different covariates (e.g. body weight, age, 
renal function) to explore the drivers of variability [38]. Pro-
pylene glycol clearance was mainly driven by birth weight 
and postnatal age [31], while hepatic elimination was a more 
relevant route of elimination (75–85% instead of 45–50%) 
when compared to observations in adults [17]. It was con-
cluded that a low (median 34 mg/kg/day) propylene glycol 
exposure was associated with renal, metabolic and hepatic 
tolerance in neonates [39, 40].
Specific issues encountered during the propylene glycol 
project related to the extent of exposure, the need for tailored 
quantification techniques and advanced PK modeling, and 
biomarkers to reflect PD effects. Most SmPCs mention the 
presence, but not the extent (mg/mL), of excipients in any 
given formulation. Even for one specific compound (e.g. 
phenobarbital), there are different formulations with differ-
ent amounts of propylene glycol or ethanol. Contemporary 
research practices in neonates are based on low volume sam-
ples (plasma, dried spot blood) and population PK mod-
eling techniques. This necessitates tailored quantification 
techniques. This has its limitations since propylene glycol 
evaporates (similar to ethanol) and consequently, the use of 
dried spot blood technique for this compound is inaccurate 
[41]. Such measurements should subsequently be combined 
with datasets containing relevant maturational (age, weight) 
and non-maturational (renal failure, impairment, perinatal 
asphyxia) covariates [42]. The biomarkers applied to assess 
renal, hepatic and metabolic tolerance of low-dose propylene 
glycol exposure in neonates are extrapolated from similar 
(in)tolerance studies in adults and all relate to accumulation 
and the subsequent osmolar changes, but do not consider 
potential maturational PD aspects [41, 42].
5  Discussion: From Knowledge to Impact
Neonates are commonly exposed to drugs that have not been 
designed, developed nor evaluated for this patient group. 
Consequently, the lack of evidence-based approaches 
increases the risk of unpredictable exposure and risk of side 
effects from potentially toxic ingredients, including excipi-
ents. In this paper, we have used the ESNEE, the SEEN 
and the propylene glycol research projects as examples to 
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show that progress can be made [3, 22, 41]. In Table 1, we 
have summarized some lessons learned from the SEEN and 
propylene glycol projects on current excipient exposure 
in neonates. Epidemiological studies hereby not only pro-
vided information on the extent of exposure but also on the 
regional patterns and variability in product availability. This 
variability in product availability also unveiled the potential 
benefit of substitution as an approach to limit EOI exposure. 
Similar, PK studies generated data excipient disposition and 
its covariates.
Knowledge on excipients in human neonates is only one 
part of the multidisciplinary expertise needed during neona-
tal drug development, as recently also reviewed in this jour-
nal [43]. Building this expertise can benefit from cross-talk 
with non-pharmaceutical disciplines, and from pooling the 
available expertise and knowledge in a dedicated repository. 
The concept of cross-talk has been suggested since excipi-
ents and decisions on safety to exposure are not unique to 
drug development, but also occur in the field of the food 
industry or agro-science [44, 45]. Choices about excipient 
exposure can occur at several stages throughout the lifecy-
cle of a drug, from product development through to clinical 
use. Making these choices requires a scalable approach to 
analyzing the overall risk, and considers the use of a given 
excipient, hazard identification, and hazard characterization. 
Combined with exposure assessment, this should result in 
risk characterization [44, 45].
The STEP (Safety and Toxicity of Excipients for Pedi-
atrics) database is a dedicated repository, initiated through 
EUPFI (European Paediatric Formulation Initiative) to 
improve the availability and access to published informa-
tion on excipients, including information on excipient 
toxicity and tolerance in neonates [46, 47]. This database 
obviously contains the available information on the PK and 
PD of excipients in neonates. However, since choices about 
excipient exposure can occur at several stages throughout 
the lifecycle of a drug, the STEP database has not only the 
ambition to be (1) a knowledge resource for rapid retrieval 
of information, but also aims to provide (2) tactical support 
for pharmaceutical scientists to screen and select excipients 
during the product development, (3) support applications of 
computational tools to predict developmental toxicity, (4) 
support regulatory filing and risk management planning, 
(5) provide a basis to assess needs on new data in children, 
including neonates [46, 47]. As demonstrated through the 
SEEN project, excipient concentrations in medicinal prod-
ucts are unfortunately difficult to obtain and often regarded 
as commercially protected information [3]. Thus, such a 
database as STEP may not reveal the quantity of excipient 
exposures from specific drug products. Therefore, excipient 
doses may still accumulate to potentially toxic levels in neo-
nates, more likely in preterm babies or during simultaneous 
exposure. This merged knowledge from the STEP database 
and other sources should result in impact, and help improve 
the quality of risk assessment and decisions on excipient use, 
applying a risk-benefit framework (explicit justification of 
excipients, plan product development early and engage all 
stakeholders, data sharing and modeling, challenges related 
to new excipients, context-sensitive risk-benefit analysis) 
[43]. A reflection on challenges and strategies to facilitate 
formulation development and provide a concept of a system-
atic risk-based approach to the prospective safety assessment 
of excipients in children has recently been published [43].
Because of the ongoing research and increasing knowl-
edge, the guidelines provided by authorities such as the 
European Medicines Agency (EMA) on excipients are also 
evolving, as reflected in the revisions of the guideline on 
excipients (ethanol, benzyl alcohol and benzoic alcohol, pro-
pylene glycol) in the label and package leaflet of medicinal 
products for human use, and the revision of the guideline 
on the pharmaceutical development of medicines for pedi-
atric use [6, 15, 26, 48]. Table 2 provides an overview of 
the tolerance limits for ethanol, propylene glycol and benzyl 
alcohol as currently proposed by EMA [15, 20, 48]. In the 
most recent version of this guideline, the topic of excipients 
and the concept of a balanced approach with a decision tree 
are provided. In essence, “although the basic considerations 
regarding the use of a specific excipient are similar for adult 
and paediatric preparations, the inclusion of any excipient 
in paediatric preparations, even those which are normally 
accepted for use in medicines for adults or those which are 
present in authorised paediatric medicines, requires special 
Table 1  Lessons learned from the ESNEE, SEEN and propylene glycol project on excipient of interest (EOI) exposure in (pre)term neonates [3, 
22, 25, 41]
ESNEE European Study on Neonatal Exposure to Excipients, SEEN Safe Excipient Exposure in Neonates and Small Children, SmPC Summary 
of Product Characteristics
Exposure is common Different cohorts in different countries all provide evidence for consistent, established exposure to EOI 
excipients in neonates
The range in exposure is extensive Despite the established exposure, there is relevant variability in the exposure to EOI
Exposure is difficult to quantify Excipients are commonly mentioned on the leaflet/SmPC, but amounts are only rarely mentioned
Exposure can be bypassed For the same active compound, there are different formulations with different exposure to EOI excipients. 
This means that to a certain extent, excipient exposure can even be avoided
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safety considerations. A conservative approach should be 
followed in case of limited safety data relevant to the use of 
an excipient in a specific age group [6]”.
6  Conclusions
In conclusion, the ESNEE project, SEEN initiative and 
propylene glycol project illustrate the feasibility of making 
progress. The information generated in these studies should 
subsequently be integrated into the STEP (Safety and Toxic-
ity of Excipients for Paediatrics) repository to enable access 
for all stakeholders involved and this pooled information 
should be used to make the best decisions to further improve 
pharmacotherapy in neonates.
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